6-Feruloylnodakenin

CAS No. 131623-14-8

6-Feruloylnodakenin( —— )

Catalog No. M31969 CAS No. 131623-14-8

6'-Feruloylnodakenin is a natural product for research related to life sciences.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1017 In Stock
10MG 1378 In Stock
25MG 2043 In Stock
50MG 2678 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    6-Feruloylnodakenin
  • Note
    Research use only, not for human use.
  • Brief Description
    6'-Feruloylnodakenin is a natural product for research related to life sciences.
  • Description
    6'-Feruloylnodakenin is a natural product for research related to life sciences.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    131623-14-8
  • Formula Weight
    584.6
  • Molecular Formula
    C30H32O12
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Vindesine sulfate

    Vindesine sulfate is a vinca alkaloid which is a synthetic derivative of vinblastine, binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

  • Yadanzioside A

    Yadanziolide A, a quassinoid glycoside from Brucea javanica, has antitumor activity.

  • PAR-3 (1-6) (human)

    PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.